Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study

被引:280
作者
Velayos, Fernando S.
Lofrus, Edward V., Jr.
Jess, Tine
Harmsen, W. Scott
Bida, John.
Zinsmeister, Alan R.
Tremaine, William J.
Sandborn, William J.
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Univ Calif San Francisco, Div Gastroenterol & Hepatol, San Francisco, CA 94143 USA
[3] Herlev Univ Hosp, Dept Med Gastroenterol C, DK-2730 Herlev, Denmark
关键词
D O I
10.1053/j.gastro.2006.03.028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Predictive and protective factors associated with colorectal cancer in chronic ulcerative colitis are not well described. Surveillance colonoscopy and 5-aminosalicylic acid therapy may mitigate cancer risk, but there is debate because these variables have not been evaluated in the same study. The presence of postinflammatory pseudopolyps and use of other anti-inflammatory medications may be important variables that influence risk, but data are sparse. Methods: Variables associated with colorectal cancer were registered in 188 patients with ulcerative colitis-related cancer and matched controls. Conditional logistic regression, adjusted for age at colitis diagnosis and colitis duration, identified a final set of variables independently associated with colorectal cancer. Results: In the final multiple variable model, the most important factors associated with colorectal cancer were a history of pseudopolyps (OR, 2.5; 95% CI: 14-4.6), 1 or 2 surveillance colonoscopies (OR, 0.4; 95% CI: 0.2-0.7), smoking (OR, 0.5; 95% CI: 0.2-0.9) and use of corticosteroids (OR, 0.4; 95% CI: 0.2-0.8), aspirin (OR, 0.3; 95% CI: 0.1-0.8), nonsteroidal anti-inflammatory drugs (OR, 0.1; 95% CI: 0.03-0.5), and 5-aminosalicylic acid agents (OR, 0.4; 95% CI: 0.2-0.9), although the latter was not statistically significant after 5 years. Primary sclerosing cholangitis and immunosuppressive use were not statistically significant. Conclusions: These results suggest that, in a population matched for extent and duration of chronic ulcerative colitis, surveillance colonoscopy and use of anti-inflammatory medications may reduce the risk of colorectal cancer. A history of postinflammatory pseudopolyps appears to be a predictive factor for cancer.
引用
收藏
页码:1941 / 1949
页数:9
相关论文
共 40 条
[1]   Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease [J].
Allgayer, H .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 :10-14
[2]  
[Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000279.PUB2
[3]   Family history as a risk factor for colorectal cancer in inflammatory bowel disease [J].
Askling, J ;
Dickman, PW ;
Karlén, P ;
Broström, O ;
Lapidus, A ;
Löfberg, R ;
Ekbom, A .
GASTROENTEROLOGY, 2001, 120 (06) :1356-1362
[4]  
Bansal P, 1996, AM J GASTROENTEROL, V91, P44
[5]   Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? [J].
Bernstein, CN ;
Blanchard, JF ;
Metge, C ;
Yogendran, M .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) :2784-2788
[6]   Challenges in designing a randomized trial of surveillance colonoscopy in IBD [J].
Bernstein, CN .
INFLAMMATORY BOWEL DISEASES, 1998, 4 (02) :132-141
[7]  
BERNSTEIN CN, 1994, LANCET, V343, P71
[8]  
Eaden J, 2000, ALIMENT PHARM THERAP, V14, P145
[9]   ULCERATIVE-COLITIS AND COLORECTAL-CANCER - A POPULATION-BASED STUDY [J].
EKBOM, A ;
HELMICK, C ;
ZACK, M ;
ADAMI, HO .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (18) :1228-1233
[10]  
GREENSTEIN AJ, 1979, GASTROENTEROLOGY, V77, P290